...
首页> 外文期刊>Mutation Research: International Journal on Mutagenesis, Chromosome Breakage and Related Subjects >A comparative study of the cytotoxic and genotoxic effects of ICRF-154 and bimolane, two catalytic inhibitors of topoisomerase II.
【24h】

A comparative study of the cytotoxic and genotoxic effects of ICRF-154 and bimolane, two catalytic inhibitors of topoisomerase II.

机译:两种拓扑异构酶II的催化抑制剂ICRF-154和联苯胺的细胞毒性和基因毒性的比较研究。

获取原文
获取原文并翻译 | 示例
           

摘要

ICRF-154 and bimolane have been used for the treatment of cancer, psoriasis, and uveitis in humans. Previous reports have revealed that the two drugs are topoisomerase II catalytic inhibitors, and patients treated with these agents have developed unique types of secondary leukemia. A study published in 1984 by Camerman and colleagues proposed that the therapeutic effects of bimolane could be due to ICRF-154, an impurity present within the bimolane samples that may also be responsible for the toxic effects attributed to bimolane. To date, this hypothesis has not been evaluated. In addition, little is known about the potential cytotoxic and genotoxic effects of ICRF-154. In this study, a combination of in vitro tests in human TK6 lymphoblastoid cells has been used to characterize the cytotoxic and genotoxic effects of ICRF-154 and bimolane as well as to compare the results for the two chemicals. ICRF-154 and bimolane were both cytotoxic, exhibiting very similar effects in three measures of cytotoxicity and cell proliferation. In the cytokinesis-block micronucleus assay with CREST-antibody staining, the two agents similarly induced chromosome breakage and, to a lesser extent, chromosome loss. Intriguingly, both drugs resulted in the formation of binucleated cells, perhaps as a consequence of an interference with cytokinesis. To further investigate their aneugenic effects, flow cytometry and fluorescence in situ hybridization analyses revealed that both compounds also produced similar levels of non-disjunction and polyploidy. In each of the cellular and cytogenetic assays employed, the responses of the ICRF-154-treated cells were very similar to those observed with the bimolane, and generally occurred at equimolar test concentrations. Our results, combined with those from previous studies, strongly suggest that bimolane degrades to ICRF-154, and that ICRF-154 is most likely the chemical species responsible for the cytotoxic, genotoxic, and leukemogenic effects exerted by bimolane.
机译:ICRF-154和联萘烷已用于治疗人类的癌症,牛皮癣和葡萄膜炎。先前的报道表明这两种药物是拓扑异构酶II催化抑制剂,用这些药物治疗的患者已发展出独特类型的继发性白血病。 Camerman及其同事在1984年发表的一项研究提出,双摩尔烷的治疗效果可能是由于ICRF-154引起的,ICRF-154是存在于双摩尔烷样品中的一种杂质,可能也归因于双摩尔烷的毒性作用。迄今为止,尚未对该假设进行评估。另外,关于ICRF-154的潜在细胞毒性和遗传毒性作用知之甚少。在这项研究中,已在人的TK6淋巴母细胞中进行了一系列体外试验,以表征ICRF-154和联苯胺的细胞毒性和遗传毒性作用,并比较两种化学物质的结果。 ICRF-154和联萘烷均具有细胞毒性,在细胞毒性和细胞增殖的三种测量中表现出非常相似的作用。在采用CREST抗体染色的胞质分裂阻滞微核试验中,两种药物类似地诱导染色体断裂,并在较小程度上诱导染色体丢失。有趣的是,这两种药物都可能导致了双核细胞的形成,这可能是干扰了细胞分裂的结果。为了进一步研究它们的气生成作用,流式细胞仪和荧光原位杂交分析显示这两种化合物也产生相似水平的非分离和多倍性。在所用的每种细胞和细胞遗传学测定中,经ICRF-154处理的细胞的反应与用双摩尔烷所观察到的反应非常相似,并且通常在等摩尔测试浓度下发生。我们的研究结果与先前的研究结果相结合,强烈表明联苯甲醛会降解为ICRF-154,而ICRF-154最有可能是由联苯甲醛引起的细胞毒性,遗传毒性和致白血病作用的化学物质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号